云知声（09678）：AGI技术产业化的先行者

Investment Rating - The report initiates coverage with a "Buy" rating for the company [1][18] Core Insights - The company is a pioneer in AGI technology commercialization, with rapid deployment of AI solutions in daily life and healthcare sectors. The AI solutions and medical markets are experiencing fast growth [2][10] - The company is expected to achieve revenues of RMB 12.68 billion, RMB 19.43 billion, and RMB 26.59 billion for the years 2025 to 2027, representing year-on-year growth rates of 35%, 53%, and 37% respectively. The net profit attributable to the parent company is projected to be -RMB 2.45 billion, -RMB 1.35 billion, and -RMB 1.04 billion for the same years, with growth rates of 46%, 45%, and 23% respectively [10][18] Financial Summary - Total revenue is projected to grow from RMB 727.32 million in 2023 to RMB 2,659.25 million by 2027, with annual growth rates of 21.1%, 29.1%, 35.0%, 53.2%, and 36.9% [4][10] - Gross profit is expected to increase from RMB 294.51 million in 2023 to RMB 1,069.12 million in 2027 [4] - The company’s net profit is forecasted to improve from -RMB 375.46 million in 2023 to -RMB 103.67 million in 2027 [4] Market Position - The company ranks fourth in the Chinese AI solutions market, with a market size of RMB 1,804 billion in 2024 and a compound annual growth rate (CAGR) of 33.7% expected until 2030 [10] - In the daily life AI solutions market, the company holds the third position, while in the medical AI market, it ranks fourth [10] Business Segmentation - Revenue from daily life solutions is projected to grow significantly, with expected revenues of RMB 622.53 million in 2024, RMB 819.79 million in 2025, and RMB 1,250.88 million in 2026 [13] - The AI medical segment is anticipated to generate revenues of RMB 199.18 million in 2024, RMB 279.33 million in 2025, and RMB 445.58 million in 2026, with growth rates of 34.36%, 40.24%, and 59.52% respectively [13][14] Valuation - The report employs two valuation methods, resulting in a target price of HKD 451.33 based on a cautious approach [18] - The PS valuation method indicates a reasonable valuation of HKD 451.33, while the PSG method suggests a higher valuation of HKD 527.62 [17][18]